Axsome Therapeutics (AXSM) Cash & Equivalents (2015 - 2026)

Axsome Therapeutics has disclosed Cash & Equivalents across 12 years of filings, most recently posting $305.1 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $305.1 million, up 1.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $305.1 million (up 1.4% YoY), and the FY2025 annual result was $322.9 million, up 2.4% from the prior year.
• Cash & Equivalents came in at $305.1 million for Q1 2026 at Axsome Therapeutics, down from $322.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $437.1 million in Q2 2023 to a low of $73.4 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $315.4 million (2024), against an average of $289.4 million.
• Across the five-year window, Cash & Equivalents slumped 48.56% in 2022 and jumped 495.57% in 2023, its largest moves.
• Axsome Therapeutics' Cash & Equivalents stood at $200.8 million in 2022, then jumped by 92.29% to $386.2 million in 2023, then fell by 18.34% to $315.4 million in 2024, then rose by 2.4% to $322.9 million in 2025, then slipped by 5.52% to $305.1 million in 2026.
• The last three Cash & Equivalents figures came in at $305.1 million (Q1 2026), $322.9 million (Q4 2025), and $325.3 million (Q3 2025), per Business Quant data.